Portal de Periódicos da CAPES

Death after misuse of anabolic substances (clenbuterol, stanozolol and metandienone)

2019; Elsevier BV; Volume: 303; Linguagem: Inglês

10.1016/j.forsciint.2019.109925

1872-6283

Sabrina Lehmann, Andreas Thomas, Karl-Heinz Schiwy-Bochat, Hans Geyer, Mario Thevis, Frank Glenewinkel, Markus A. Rothschild, Hilke Andresen‐Streichert, Martin Juebner,

Pharmacology and Obesity Treatment

A 34-year old male was found breathless and panting at home by his girlfriend three hours after a gym workout. Minutes later, he collapsed and died. Autopsy, histological and chemical analyses were conducted. The examination of the heart showed left ventricular hypertrophy, while the right coronary artery showed only a small vascular lumen (3 mm in diameter), due to its anatomical structure. In femoral blood concentrations of approx. 1 μg/L clenbuterol, approx. 56 μg/L stanozolol and approx. 8 μg/L metandienone, with trenbolone (<limit of quantification (LOQ)) were detected. Additionally, there were positive results in urine for boldenone, clomiphene, trenbolone, metandienone, stanozolol, clenbuterol and drostanolone, along with indications of testosterone and/or testosterone prohormones having been taken. In consideration of all aspects of this case, in can be assumed that the long-term consumption of anabolic androgen steroids (AAS) caused apparently pathological changes of the heart. Over and above, the combination of anatomical (small lumed coronary artery, ventricular hypertrophy) and substance-induced risk factors led to the fatal cardiovascular failure.